SMMT vs. TEM: Summit Therapeutics vs. Tempus AI Stock Comparison

Company Profile

Summit Therapeutics (SMMT) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SMMT is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

Summit Therapeutics (SMMT) has been public since March 5, 2015, giving it a longer listed trading history, while Tempus AI (TEM) listed on June 14, 2024 and still has a shorter public-market record.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Tempus AI (TEM) has a non-negative beta of 3.34.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Summit Therapeutics (SMMT) at -220.01% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: Tempus AI (TEM) reports revenue growth of 83.41%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Neither Summit Therapeutics (SMMT) nor Tempus AI (TEM) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Summit Therapeutics (SMMT) at 5.99 and Tempus AI (TEM) at 2.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Summit Therapeutics (SMMT) at 0.04 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Summit Therapeutics (SMMT) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Summit Therapeutics (SMMT) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither Summit Therapeutics (SMMT) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

A sales-based read is only available for Tempus AI (TEM), whose P/S ratio of 9.19 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Measured against book value, both Summit Therapeutics (SMMT) at 23.13 and Tempus AI (TEM) at 27.66 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics